Overview

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Status:
RECRUITING
Trial end date:
2027-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
Phase:
PHASE4
Details
Lead Sponsor:
AstraZeneca
Treatments:
dapagliflozin